Navigation Links
Sangamo BioSciences Announces Presentation of Clinical Data Demonstrating Functional Control of Viremia in HIV-Infected Subjects Treated with SB-728-T
Date:9/12/2013

are generally not susceptible to the most common strain of HIV.

Summary of Clinical Trial Design
About SB-728-902 Cohorts 1-3
The study is an open-label Phase 1 clinical trial to evaluate the safety and tolerability of single infusions of an escalating dose of an autologous (a patient's own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). The trial enrolled nine HIV-infected subjects (three cohorts of three subjects each) who have sub-optimal T-cell levels and no detectable viral load on long-term ART.  Subjects remained on their existing antiviral therapy while receiving treatment with SB-728-T.

About SB-728-902 Cohort 5
Up to 20 HIV-infected subjects heterozygous for the CCR5 delta-32 mutation (i.e. with one CCR5 gene that is naturally modified) who are currently on ART are being enrolled and will receive a single intravenous infusion of SB-728-T (5 to 30 billion modified cells). Two months after SB-728-T treatment, subjects undergo a 16 week TI during which time their ART is discontinued. ART will be reinstituted in subjects whose CD4 T-cell counts drop to <350 cells/ mm3 and/or whose HIV-RNA increases to >100,000 /mL for three consecutive weekly measurements. At the end of the TI, subjects with a sustained detectable HIV viral load are reinstituted on ART. Subjects with an undetectable viral load can remain off ART until HIV RNA levels are detectable or their CD4 T-cell count drops below 350 cell/mm3 for three consecutive weekly measurements.

A total of ten subjects have been treated in this cohort. 

Of the six evaluable subjects, we observed two subjects in which their VL became undetectable during TI from ART:

  • In one subject, VL suppression at, or below, the limit of quantification (LOQ) of virus was sustained from week 11 – 19 of TI and the TI is ongoing.
  • In the s
    '/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Sangamo BioSciences to Acquire Ceregene
2. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
3. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
4. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
5. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
6. Sangamo BioSciences Reports First Quarter 2013 Financial Results
7. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
9. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
10. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
11. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... /CNW Telbec/ - Russell Williams , President of ... welcomes the 2015-2016 Quebec Budget, noting the fiscal discipline ... biopharmaceutical industry. However, the association is concerned about the ... the government,s intent to strive for a balanced budget ... Quebec,s economic development is encouraging," ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
(Date:3/27/2015)... , March 27, 2015 A new report from ... America – Chile , ... are top targets for IVD firms.  The healthcare research firm ... into IVD strategies for the Latin American continent with a ... globally distributed supply operations. However, the country,s regional economic clout ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
... to confirmed EDSS progression reduced by 40 percent ... – Bayer Schering Pharma AG,Germany, announced today new ... beta-1b) treatment in,patients with a first event suggestive ... of permanent neurological,impairment as measured by the Expanded ...
... efficacy across the range of migraine symptoms, BOSTON, ... experience traditional symptoms such as nausea or,sensitivity to ... like neck pain or sinus pain that are ... that,significantly more patients using the investigational migraine,treatment Trexima ...
Cached Medicine Technology:Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability 2Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability 3Immediate Treatment of Early MS Patients with Betaferon,Significantly Delayed Permanent Disability 4Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 2Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 3Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 4Trexima (Sumatriptan/Naproxen Sodium) Provided Relief of Both,Traditional and Non-traditional Migraine Symptoms 5
(Date:3/27/2015)... According to Health Day , on ... Abstinence Syndrome (NAS) are causing alarm for Florida officials. ... process for a month of their lives- and can ... vomiting. The condition is precipitated by drug use during ... (and employing medically assisted drug treatment) will also inflict ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global ... the SM1120 MEMS based ultra-miniature pressure sensor designed especially ... at only 220um x 75um provides ample space for ... With industry leading in vivo drift performance of ... broad operating pressure range from 0 to 1,100 mmHg ...
(Date:3/27/2015)... OR (PRWEB) March 27, 2015 California’s ... winter blizzards in Boston and the United States Northeast, ... patterns. Earth warming global atmosphere is creating changes in ... PhD, historical climatologist and former NASA researcher, speaking on ... The result is not only a warmer and dryer ...
(Date:3/27/2015)... 2015 Operatic contenders and their avid ... April 17th. The universally acclaimed baritone Sherrill Milnes will ... Opera Idol at The Merion in Evanston. The event ... drawn aspiring opera singers from around the country. “This ... the finest young talent in the country,” said Margaret ...
(Date:3/27/2015)... To address their number one lawn care question ... filming this video to explain the complicated dynamics between the ... often expected to thrive in, be it in dense building ... survive. Anytime a sun-loving plant is put in the shade ... homeowners try to amend this issue by applying large quantities ...
Breaking Medicine News(10 mins):Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Opera Idol Competition At The Merion In Evanston 2Health News:For Spring Turf Planting Season, Super-Sod Created a New How-To Video Entitled "Two Views on Shade and Turf" 2
... treatment could prevent several bone problems, , TUESDAY, Oct. 27 ... treatment with large doses of vitamin D2 can eliminate vitamin ... bay for up to six years. , The dosage ... was large but did not appear to be toxic, according ...
... ... vast reach across the U.S. healthcare industry with Susan G. Komen,s mission to cure ... ... with Susan G. Komen for the Cure®, the world,s largest breast cancer advocacy organization. ...
... Robert A. Douglas, 1st Vice President Senior Consultant Sales, ... Career Division national sales growth, Expansion of new RJR sales ... management experience and over 6 years of sales training experience ... in the development and implementation of several new divisions to ...
... Vestara, ... has been awarded a MedAssets supplier contract. MedAssets serves more than 1,700 hospitals and ... ... provider of the industry,s only automated pharmaceutical waste management solution, announced today that it ...
... , ... Homonculus Press, Mexico City, announces the publication of The American ... revealed two sets of parties of interest: A complaint against the first ... 24 Feb 2006 at the Lumpini Police Station against Bumrungrad International Hospital ...
... ... ... -- Morehead, the human capital research firm, will host a webinar titled "A Two-Pronged Strategy ... 17, 2009 at 1:00 p.m. EST. , , ,In this webinar, David Rowlee, Ph.D., ...
Cached Medicine News:Health News:Short-Term, High-Dose Vitamin D2 May Ease Deficiency 2Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 2Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 3Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 4Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 2Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 3Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 4Health News:Vestara Awarded MedAssets Supplier Contract For Automated Pharmaceutical Waste Management Solution 2Health News:The American Medical Money Machine, the Destruction of Healthcare in America and the Rise of Medical Tourism, a New Book by James R. Goldberg 2Health News:The American Medical Money Machine, the Destruction of Healthcare in America and the Rise of Medical Tourism, a New Book by James R. Goldberg 3Health News:The American Medical Money Machine, the Destruction of Healthcare in America and the Rise of Medical Tourism, a New Book by James R. Goldberg 4Health News:The American Medical Money Machine, the Destruction of Healthcare in America and the Rise of Medical Tourism, a New Book by James R. Goldberg 5Health News:Morehead Presents Webinar on 'A Two-Pronged Strategy to Reduce Nurse Turnover' 2
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
... Tendril SDX is one ... pacing leads. Implantable with a ... reduced body diameter is designed ... venous obstruction and allow introduction ...
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
Medicine Products: